10 Stocks That Will Make You Rich In 2025

7. Corcept Therapeutics Incorporated (NASDAQ:CORT)

Analysts Upside Potential: 47.86%

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a pharmaceutical company that specializes in creating drugs that adjust how cortisol affects the body. Cortisol is a hormone that plays a crucial role in various bodily functions, but too much of it can lead to serious health issues. Its main product is Korlym (mifepristone), which is approved by the FDA for treating Cushing’s syndrome, a condition caused by excess cortisol.

During the fiscal third quarter of 2024, the company continued to add prescribers and more patients for Korlym. This resulted in its revenue growing 48% year-over-year to reach $182.5 million. Management noted that there is a rising awareness among physicians about hypercortisolism, leading to more screenings and treatments for affected patients. This shift is critical as it allows more individuals to receive necessary care. In addition to Korlym, Corcept Therapeutics Incorporated (NASDAQ:CORT) is preparing to submit a New Drug Application (NDA) for Relacorilant, by the end of the year. Relacorilant is a medication that also treats people with Cushing’s syndrome.

As the company anticipated approval for its Cushing syndrome, management has raised its full-year guidance for 2024. It now expects revenue in the range of $675 million and $700 million. ClearBridge Small Cap Value Strategy indicated an attractive growth runway for Corcept Therapeutics Incorporated (NASDAQ:CORT) considering the likelihood of FDA approval. Here’s what ClearBridge Small Cap Value Strategy stated regarding Corcept Therapeutics Incorporated (NASDAQ:CORT) in its Q2 2024 investor letter:

“Health care results lifted relative performance during the period and included our top two individual performers in Lantheus and newer portfolio addition Corcept Therapeutics Incorporated (NASDAQ:CORT). Corcept, which was added last quarter, announced that it had successfully reached its main goal in its Phase 3 trial for its treatment for patients with Cushing’s syndrome. We believe the new drug’s efficacy and safety significantly increases its likelihood of approval and offers an attractive growth runway via possible extension into other indications.”